---
title: "Alpha Tau REGAINs Momentum On Brain Cancer Study Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285940718.md"
description: "Shares of Alpha Tau Medical Ltd. (DRTS) rose over 12% to $9.60 in premarket trading following positive interim results from its REGAIN trial for recurrent glioblastoma. The study, which aims to assess the safety and feasibility of Alpha DaRT treatment, showed that two out of three patients had a complete response, with no visible tumor lesions. Chief Medical Officer Robert Den expressed optimism about the results, highlighting the potential for advancing the trial."
datetime: "2026-05-11T12:20:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285940718.md)
  - [en](https://longbridge.com/en/news/285940718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285940718.md)
---

# Alpha Tau REGAINs Momentum On Brain Cancer Study Data

Add  as your preferred news source on Google

 Add Now

Shares of Alpha Tau Medical Ltd. (DRTS) are up over 12% at $9.60 in premarket trading on Monday, following encouraging interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, dubbed REGAIN.

The REGAIN study is a prospective, open-label, single-arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma, the most common and aggressive form of brain cancer.

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to deliver radium-224 directly into tumors to release strong, localized alpha radiation that precisely targets and destroys solid cancer cells.

Glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months, according to the National Brain Tumor Society.

The REGAIN study is designed to enroll 10 brain cancer patients and the interim results reported today were from the first three treated patients.

According to the trial results, two of the three treated patients showed a complete response, with total disappearance of all enhancing tumor lesions on multiple post-treatment MRI scans.

Commenting on the study results, Robert Den, Chief Medical Officer of Alpha Tau, said, "It is immensely gratifying to see these interim results of our recurrent glioblastoma protocol. In a disease where median survival after recurrence is typically under 12 months and where promising approaches have repeatedly failed to translate to successful outcomes, this profile of activity and tolerability gives us strong rationale to advance the trial toward full accrual."

When we alerted readers to DRTS on December 11, 2025, it was at $5. The stock closed Friday's (May 8, 2026) trading at $8.51, up 8.41%.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md)

## Related News & Research

- [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md)
- [Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT](https://longbridge.com/en/news/285960241.md)
- [Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit | WHWK Stock News](https://longbridge.com/en/news/287060019.md)
- [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md)
- [Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data](https://longbridge.com/en/news/286990060.md)